Altamira Therapeutics

Altamira Therapeutics is a pioneering force in pharmaceutical manufacturing, dedicated to the development of innovative RNA-based therapeutics aimed at extrahepatic targets. Utilizing cutting-edge delivery platforms such as OligoPhore™, SemaPhore™, and CycloPhore™, Altamira Therapeutics is at the forefront of medical advancement. With a focus on precision and efficacy, the company is committed to transforming patient care through targeted therapies. The company maintains operations in Basel, Switzerland and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics is currently advancing two flagship siRNA programs through preclinical development, both of which have achieved in vivo proof of concept. AM-401 targets KRAS driven cancer, while AM-411 is being developed for the treatment of rheumatoid arthritis. These programs underscore the company's commitment to addressing critical medical needs with novel therapeutic solutions. Altamira Therapeutics is also in the process of refining its portfolio, focusing on its core RNA-based technologies while divesting legacy assets in allergology, viral infections, and inner ear therapeutics.

Altamira Therapeutics is strategically positioned for growth and innovation in the pharmaceutical sector. The company's dedication to research and development, combined with its focus on targeted RNA therapies, makes it a key player in the future of medicine. We invite the management of Altamira Therapeutics to create a customized and exclusive company showcase and product listing on our platform, providing a unique opportunity to highlight your advancements and connect with a broader audience.